GIP and GLP-1 in Type 1 Diabetes

计划入组 10 人 · 首次发布于 2012 年 12 月 3 日

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

计划入组 150 人 · 首次发布于 2025 年 7 月 30 日

Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.

计划入组 140 人 · 首次发布于 2026 年 7 月 30 日

rHSA-GLP-1

GLP-1 derivative

APB-GLP-1

NHI-1

United States

OS Therapies

United States

Biorestorative Therapies

United States

Kailera Therapeutics Launches with $400M to Advance GLP-1 Based Obesity Therapies

GLP-1 Therapies Expand Beyond Diabetes: Promising Results in Cardiovascular, Renal, and Liver Diseases

Biomea Fusion Pivots to Diabetes and Obesity, Prioritizing Icovamenib Development